Resibufogenin Suppresses Triple-Negative Breast Cancer Angiogenesis by Blocking VEGFR2-Mediated Signaling Pathway
Resibufogenin (RBF), an active compound from Bufo bufonis, has been used for the treatment of multiple malignant cancers, including pancreatic cancer, colorectal cancer, and breast cancer. However, whether RBF could exert its antitumor effect by inhibiting angiogenesis remains unknown. Here, we aime...
Saved in:
Main Authors: | Ting Yang (Author), Yi-Xin Jiang (Author), Ye Wu (Author), Dong Lu (Author), Rui Huang (Author), Long-Ling Wang (Author), Shi-Qi Wang (Author), Ying-Yun Guan (Author), Hong Zhang (Author), Xin Luan (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tussilagone Suppresses Angiogenesis by Inhibiting the VEGFR2 Signaling Pathway
by: Jia Li, et al.
Published: (2019) -
Saikosaponin A, a Triterpene Saponin, Suppresses Angiogenesis and Tumor Growth by Blocking VEGFR2-Mediated Signaling Pathway
by: Pan Zhang, et al.
Published: (2021) -
Lenvatinib Suppresses Angiogenesis through the Inhibition of both the VEGFR and FGFR Signaling Pathways
by: Kenji Ichikawa, et al.
Published: (2016) -
Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent
by: Zongru Jiang, et al.
Published: (2020) -
Gambogic amide inhibits angiogenesis by suppressing VEGF/VEGFR2 in endothelial cells in a TrkA-independent manner
by: Tongtong Sui, et al.
Published: (2021)